Enzo Biochem Inc. (NYSE:ENZ) went up by 6.25% from its latest closing price compared to the recent 1-year high of $4.85. The company’s stock price has collected 5.59% of gains in the last five trading sessions. Press Release reported on 06/09/21 that Enzo Biochem Reports Third Quarter Fiscal 2021 Results
Is It Worth Investing in Enzo Biochem Inc. (NYSE :ENZ) Right Now?
Enzo Biochem Inc. (NYSE:ENZ) scored a price-to-earnings ratio above its average ratio, recording 131.78 x from its present earnings ratio. Plus, the 36-month beta value for ENZ is at 0.89. Opinions of the stock are interesting as 1 analysts out of 1 who provided ratings for Enzo Biochem Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $5.50. ENZ currently public float of 44.43M and currently shorts hold a 3.70% ratio of that float. Today, the average trading volume of ENZ was 1.24M shares.
ENZ’s Market Performance
ENZ stocks went up by 5.59% for the week, with a monthly jump of 14.86% and a quarterly performance of 16.04%, while its annual performance rate touched 34.92%. The volatility ratio for the week stands at 5.28% while the volatility levels for the past 30 days are set at 5.06% for Enzo Biochem Inc.. The simple moving average for the period of the last 20 days is 10.95% for ENZ stocks with a simple moving average of 25.84% for the last 200 days.
Analysts’ Opinion of ENZ
Many brokerage firms have already submitted their reports for ENZ stocks, with Rodman & Renshaw repeating the rating for ENZ by listing it as a “Mkt Outperform.” The predicted price for ENZ in the upcoming period, according to Rodman & Renshaw is $5 based on the research report published on October 18th of the previous year 2011.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see ENZ reach a price target of $14. The rating they have provided for ENZ stocks is “Mkt Outperform” according to the report published on September 23rd, 2009.
Lazard Capital gave a rating of “Buy” to ENZ, setting the target price at $19 in the report published on September 13th of the previous year.
ENZ Trading at 7.07% from the 50-Day Moving Average
After a stumble in the market that brought ENZ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -29.90% of loss for the given period.
Volatility was left at 5.06%, however, over the last 30 days, the volatility rate increased by 5.28%, as shares surge +17.65% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +3.34% upper at present.
During the last 5 trading sessions, ENZ rose by +5.59%, which changed the moving average for the period of 200-days by +49.12% in comparison to the 20-day moving average, which settled at $3.09. In addition, Enzo Biochem Inc. saw 34.92% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at ENZ starting from HARBERT MANAGEMENT CORP, who sale 300,000 shares at the price of $4.65 back on Mar 16. After this action, HARBERT MANAGEMENT CORP now owns 5,175,913 shares of Enzo Biochem Inc., valued at $1,393,900 using the latest closing price.
HARBERT MANAGEMENT CORP, the 10% Owner of Enzo Biochem Inc., sale 144,768 shares at $4.83 during a trade that took place back on Mar 15, which means that HARBERT MANAGEMENT CORP is holding 5,475,913 shares at $698,840 based on the most recent closing price.
Stock Fundamentals for ENZ
Current profitability levels for the company are sitting at:
- -31.09 for the present operating margin
- +31.27 for the gross margin
The net margin for Enzo Biochem Inc. stands at -37.52. The total capital return value is set at -25.94, while invested capital returns managed to touch -33.48. Equity return is now at value -17.50, with -9.30 for asset returns.
Based on Enzo Biochem Inc. (ENZ), the company’s capital structure generated 56.22 points at debt to equity in total, while total debt to capital is 35.99. Total debt to assets is 29.16, with long-term debt to equity ratio resting at 36.58. Finally, the long-term debt to capital ratio is 23.42.
When we switch over and look at the enterprise to sales, we see a ratio of 1.30, with the company’s debt to enterprise value settled at 0.33. The receivables turnover for the company is 7.65 and the total asset turnover is 0.69. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.10.